国金证券发布研报称，维持远东宏信(03360)"买入"评级。公司金融业务经营稳健，宏信建发海外业务 贡献有望提升，预计2026-2028年公司归母净利润同比增速分别为4%/5%/5%，BPS为10.97/11.13/11.28 元。 国金证券主要观点如下： 业绩简评 2026年3月11日，远东宏信发布2025年年度业绩。2025年远东宏信实现收入总额357.85亿元，同比下降 5.2%，主要受产业运营收入下降影响;归母净利润38.89亿元，同比增长0.7%;加权平均净资产收益率为 7.71%，同比降低0.09pct，业绩符合预期。 公司利息收入同比增长3%至218.07亿元，占营收比重61% ①生息资产规模：生息资产平均余额同比小幅增长1.4%至2664亿元。其中，普惠金融业务稳健扩张， 生息资产规模同比增长55%至225亿元。②净利差：2025年净利息差同比增长0.39pct至4.39%，主要得益 于资产端收益率提升0.12pct至8.18%，成本端资金率受益于境内外降息同比下降0.27pct。③资产质量： 2025年末不良率为1.03%，同比下降0.04pct。"30+比例"同比下降0.08pct至0.8 ...

临床试验进展不及预期、核心产品销售及市场推广不及预期、市场竞争格局恶化风险。 创新管线进展顺利，多项管线实现对外授权 公司自免领域创新研发能力突出，2025年完成三条自免双抗管线对外授权，分别为授权Winddward Bio 在海外开发及商业化QX027N(TSLPxIL-13双抗)的独家权利，TSLP/IL-33双抗以10.7亿美金总包授权于 罗氏，5.55亿美元总包授权于Caldera长效双抗QX030N。该行认为公司双抗管线的密集授权证明公司研 发能力受到外部充分认可;在国内市场方面，公司研发的QX001S(IL12/23p40)与QX005N(IL-4Rα)已与华 东医药达成商业化合作，同时IL-23p19与TSLP管线分别与国内头部药企翰森制药与健康元达成合作， 未来有望借助合作药企销售渠道与市场推广资源实现产品快速销售放量。 风险提示 智通财经APP获悉，国泰海通证券发布研报称，首次覆盖给予荃信生物-B(02509)"增持"评级。公司聚焦 自身免疫及过敏性疾病生物疗法，全面布局自免领域四大疾病，包括皮肤、风湿、呼吸道及消化道疾病 的产品管线，目前以皮肤疾病为优先发展方向，公司目前拥有1项获批产品， ...

消息面上，3月11日，据康龙化成官微消息，公司与礼来公司共同宣布，达成关于首个申报注册的口服 小分子GLP-1受体激动剂Orforglipron的生产合作协议。根据协议，礼来公司预期投资康龙化成2亿美元 并支持其技术能力建设，未来将根据后续发展情况进一步扩大合作规模。此次与礼来公司就 Orforglipron达成制剂商业化生产合作，是公司制剂CDMO的重要里程碑。 智通财经APP获悉，康龙化成(03759)高开逾5%，截至发稿，涨5.43%，报19.61港元，成交额642.62万港 元。 ...

Core Viewpoint - The report from Guotai Junan Securities initiates coverage on Qianxin Biologics-B (02509) with a "Buy" rating, highlighting the company's focus on immunotherapy and allergy disease biotherapies, with a comprehensive pipeline targeting four major autoimmune diseases [1] Group 1: Company Overview - Qianxin Biologics is concentrating on immunotherapy for autoimmune and allergic diseases, prioritizing skin diseases in its product pipeline [1] - The company currently has one approved product, nine products in development, and over 20 IND-approved projects [1] Group 2: Market Potential - According to Frost & Sullivan, the global autoimmune drug market is expected to reach $176.7 billion by 2030, with the share of biopharmaceuticals increasing from 72.8% in 2022 to 82.1% in 2030 [1] - The Chinese autoimmune market is projected to reach $19.9 billion by 2030, with a compound annual growth rate (CAGR) of 26.7% from 2025 to 2030, and the share of biopharmaceuticals expected to rise from 41.9% in 2022 to 69.3% in 2030 [1] Group 3: Pipeline Progress - The company has demonstrated strong innovation capabilities in the autoimmune field, with plans to complete three dual-antibody pipelines for external licensing by 2025 [2] - The company has granted exclusive rights to Windward Bio for the overseas development and commercialization of QX027N (TSLPxIL-13 dual antibody) and has secured total licensing agreements of $1.07 billion with Roche and $555 million with Caldera for other dual antibodies [2] - In the domestic market, partnerships have been established with East China Pharmaceutical for QX001S (IL12/23p40) and QX005N (IL-4Rα), as well as collaborations with leading domestic pharmaceutical companies for further commercialization [2]

Core Viewpoint - The news highlights the progress of Huasheng Lithium's IPO in Hong Kong, aiming to enhance its international brand recognition and support its global business expansion in the lithium battery sector [1][6]. Company Overview - Huasheng Lithium plans to issue H-shares and list on the Hong Kong Stock Exchange to meet international strategic needs and enhance brand visibility [1]. - The company specializes in electrolyte additives for lithium batteries, with key products including Vinylene Carbonate (VC), Fluoroethylene Carbonate (FEC), and Lithium Bis(oxalate)borate (BOB) [1][2]. - As of mid-2025, Huasheng Lithium has four production bases, with an annual production capacity of 14,000 tons for VC and FEC, maintaining a leading position in the industry [2]. Financial Performance - Huasheng Lithium's revenue from 2019 to 2021 showed significant growth, with revenues of 423 million, 445 million, and 1.014 billion yuan respectively, and net profits increasing from 76.08 million to 417.50 million yuan [3]. - In 2022, the company faced a decline in revenue and net profit due to an oversupply in the lithium battery market, leading to a drop in product prices, particularly for VC [4]. - By 2025, the company reported a revenue of 869 million yuan, a 72.21% increase year-on-year, and achieved a net profit of 13.27 million yuan, marking a turnaround from previous losses [4]. Market Dynamics - The prices of VC and FEC saw significant increases in 2025, with VC prices rising from under 50,000 yuan per ton to as high as 250,000-300,000 yuan per ton by December [5]. - The strong demand in the energy storage and power battery markets is expected to sustain growth in the industry, providing a solid foundation for Huasheng Lithium's performance [5]. IPO Implications - Successful completion of the IPO will broaden Huasheng Lithium's financing channels, optimize its capital structure, and enhance its brand influence in the global market [6]. - The IPO is part of a broader trend of lithium battery companies seeking dual listings in A+H shares to capitalize on international capital and support global expansion [7][13]. Industry Trends - The lithium battery sector is witnessing a wave of A+H share listings, with several leading companies like Tianci Materials and New Zobon also pursuing Hong Kong listings to enhance their global competitiveness [7][12]. - The increasing penetration of electric vehicles and the expansion of the energy storage market are driving steady growth in electrolyte demand, prompting domestic companies to accelerate their international strategies [13].

Core Viewpoint - The recent transfer of shares in Guangzhou Rural Commercial Bank from China Merchants Bank to Citibank indicates a significant shift in shareholder structure, with a market value of HKD 521 million, representing 13.08% of the bank's total shares [1] Group 1: Shareholder Changes - On March 11, Guangzhou Rural Commercial Bank's shares were transferred from China Merchants Bank to Citibank, reflecting a strategic repositioning among major shareholders [1] - The market capitalization of the shares involved in the transfer is HKD 521 million, which constitutes 13.08% of the bank's total shares [1] Group 2: Corporate Governance - Guangzhou Rural Commercial Bank has received approval from the Guangdong Regulatory Bureau of the National Financial Supervisory Administration for Mr. Zhu Guilong to serve as an independent director [1] - Mr. Zhu's term is set to begin on February 14, 2026, and will last until the end of the fourth board of directors' term, with the possibility of re-election [1]

Group 1: Industry Overview - In February, the sales of new energy vehicles in China reached 765,000 units, representing a year-on-year decline of 14.2% [1] - The production and sales of new energy vehicles were 694,000 units and 765,000 units respectively, with a year-on-year decrease of 21.8% and 14.2% [1] - New energy vehicles accounted for 42.4% of total new car sales in February [1] Group 2: Company Updates - BYD officially joined the International Automotive Task Force (IATF) as a new member [2] - Tesla's Shanghai Gigafactory delivered 58,600 units in February, marking a significant year-on-year increase of 91% [2] - Xiaomi's YU7 model sold 20,196 units in February, ranking among the top three in national passenger car sales [2] Group 3: Material Costs and Pricing - NIO's founder Li Bin stated that rising prices of memory and other raw materials could increase costs for high-end models by approximately 3,000 to 5,000 yuan, totaling nearly 10,000 yuan [3] - NIO currently has no plans to adjust prices despite the cost pressures [3] Group 4: Sales Performance - JAC Motors reported a sales figure of 20,300 units in February, reflecting a year-on-year decline of 24.51% [4] - Cumulatively, JAC's sales for January and February reached 55,100 units, down 11.78% compared to the same period last year [4] - Aion's i60 model has achieved cumulative sales of over 28,000 units since its launch [5] Group 5: Innovations and Patents - Xiaomi Automotive applied for a patent related to a method for determining parking spaces, which can identify parking spots even when obstructed by obstacles [6] Group 6: Recalls and Safety - BMW China announced a recall of 147,830 imported vehicles due to potential issues with the starter motor that could lead to starting difficulties and fire risks [7] - BMW will replace the affected starter motors free of charge to eliminate safety hazards [8] Group 7: Management Changes - BMW Group appointed Raymond Wittmann as the new member of the management board responsible for production, effective May 13 [9]

Core Viewpoint - The article highlights the top ten stocks with net financing purchases on March 11, indicating strong investor interest in these companies [1] Group 1: Top Stocks by Net Financing Purchases - Haibo Technology leads with a net purchase of 297 million yuan [1] - Minsheng Bank follows with a net purchase of 204 million yuan [1] - China Power Construction ranks third with a net purchase of 185 million yuan [1] - Huahong Semiconductor has a net purchase of 180 million yuan [1] - Ningbo Construction reports a net purchase of 157 million yuan [1] - Aero Engine Corporation of China sees a net purchase of 149 million yuan [1] - Kingsoft Office has a net purchase of 142 million yuan [1] - GaoNeng Environment reports a net purchase of 142 million yuan [1] - Kweichow Moutai has a net purchase of 139 million yuan [1] - Cambridge Technology rounds out the list with a net purchase of 131 million yuan [1]

广州农商银行此前发布公告，该行收到国家金融监督管理总局广东监管局的批复，国家金融监督管理总 局广东监管局已核准朱桂龙先生(朱先生)任本行独立董事，任期自2026年2月14日起至第四届董事会任 期届满为止，任期届满后可以连选连任。 香港联交所最新资料显示，3月11日，广州农商银行(01551)股东将股票由招商银行转入花旗银行，转仓 市值5.21亿港元，占比13.08%。 ...

佰泽医疗截至2025年6月30日止六个月的中期业绩显示，收入5.75亿元(人民币，下同)，同比增加0.66%; 股东应占亏损2762万元，同比扩大139.18%;每股基本亏损0.02元。 香港联交所最新资料显示，3月11日，佰泽医疗(02609)股东将股票存入中信证券经纪香港，存仓市值 2.89亿港元，占比6.66%。 ...